Ticagrelor Tablet
Product Images NDC 72516-017

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Ticagrelor (NDC 72516-017). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Oryza Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure_1 (Figure 1)

Figure_1 (Figure 1)
This is a comparison between Tigomg and Clopidogrel for patients with events and their outcomes over 12 months. It shows the number of patients with events, Kaplan-Meier percentage at 12 months, days from the first study drug dose, and patients at risk for both medications.*
FDA Label Image

Fiigure_2 (Figure 2)

Fiigure_2 (Figure 2)
FDA Label Image

Chemical Structure (Chemical Structure)

Chemical Structure (Chemical Structure)
FDA Label Image

Figure_8 (Figure 08)

Figure_8 (Figure 08)
This is a list of drug interactions with Ticagrelor AR-C124910XX based on the strength of the inhibitor or inducer. It includes recommendations for strong CYP3A4 inhibitors and potent CYP3A4 inducers, with advice to avoid concomitant use. It also gives guidance on moderate CYP3A inhibitors, P-gP and CYP3A inhibitors, and provides dosage adjustment recommendations for certain drugs like Aspirin, Desmopressin, Heparin, and Enoxaparin.*
FDA Label Image

Figure_10 (Figure 10)

Figure_10 (Figure 10)
This text contains data related to the effectiveness of Clopidogrel in patients with cardiovascular events over a period of 12 months. The numbers show the percentage of patients with events in the Clopidogrel group compared to the control group at different time points. The text displays the results in a graphical format with days from randomization on the X-axis and the number of patients at risk on the Y-axis for both treatment groups.*
FDA Label Image

Figure_11 (Figure 11)

Figure_11 (Figure 11)
FDA Label Image

Figure_12 (Figure 12)

Figure_12 (Figure 12)
FDA Label Image

Figure_13 (Figure 13)

Figure_13 (Figure 13)
FDA Label Image

Figure_14 (Figure 14)

Figure_14 (Figure 14)
This text contains statistical data on the characteristics of subjects in a study, including demographics, treatment effects, medical history, and clinical outcomes related to Ticagrelor usage. The data includes information about age distribution, weight, race, medical conditions, smoking status, and treatment duration. It also compares the outcomes between Ticagrelor and Placebo groups in the study, presenting the Hazard Ratios (HR) and corresponding confidence intervals. The findings suggest variations in outcomes between the two treatment groups, highlighting the potential advantages of Ticagrelor over Placebo in specific clinical scenarios.*
FDA Label Image

Figure_15 (Figure 15)

Figure_15 (Figure 15)
FDA Label Image

Figure_16 (Figure 16)

Figure_16 (Figure 16)
This analysis provides data on the effect of ticagrelor versus placebo in patients with varying characteristics such as age, sex, race, body mass index, geographic region, aspirin dose, HbA1c levels, eGFR, insulin use, history of angina, multivessel coronary artery disease, history of PCI, PCI with stent, time since most recent PCI, history of CABG, time since most recent CABG, current smoker status, and duration of diabetes. The data shows hazard ratios (HR) with 95% confidence intervals, event rates, and percentages across different subgroups, indicating the impact of these factors on the effectiveness of ticagrelor compared to placebo. This detailed information can help in understanding how these characteristics may influence the outcomes of treatment with ticagrelor.*
FDA Label Image

Figure_17 (Figure 17)

Figure_17 (Figure 17)
The extracted text seems to represent data related to clinical trials comparing the efficacy of Ticagrelor 90 mg bd (twice a day) to a Placebo for preventing certain events. The data includes the number of events that occurred in each group and the number of participants at risk over time. The text also mentions the days from randomization in the study. The analysis appears to be part of a clinical trial report or research study.*
FDA Label Image

Figure_18 (Figure 18)

Figure_18 (Figure 18)
This shows a detailed breakdown of the patient population based on various factors such as age, sex, race, weight, geographic region, diagnosis of the index event, diabetes mellitus, hypertension, smoking status, among others. Additional information includes percentage data on the distribution of patients among different categories. Furthermore, there is a comparison between the effects of Ticagrelor and Placebo based on certain characteristics and outcomes, with corresponding Hazard Ratios and 95% Confidence Intervals provided for each comparison. This data appears to be from a clinical study or trial involving different patient groups receiving different treatments.*
FDA Label Image

Figure_3 (Figure 3)

Figure_3 (Figure 3)
This data table provides information on the number of participants (N) for Ticagrelor and Placebo over time (in months) from randomization. For example, at 3 years (36 months) from randomization, there were 9562 participants in the Ticagrelor group and 9531 participants in the Placebo group. The table also shows the cumulative percentage over time for each group.*
FDA Label Image

Figure_4 (Figure 4)

Figure_4 (Figure 4)
This text seems to be a cumulative table indicating event percentages for different treatments (Ticagrelor 90 mg and Placebo) as well as the number of events and cumulative percentage over a certain number of days from randomization. The data includes the number of events, number of participants, and percentage for each treatment group. It appears to be related to a clinical or research study.*
FDA Label Image

Figure_5 (Figure 5)

Figure_5 (Figure 5)
FDA Label Image

Figure_6 (Figure 6)

Figure_6 (Figure 6)
Not available.*
FDA Label Image

Figure_7 (Figure 7)

Figure_7 (Figure 7)
This is a table presenting recommendations for Ticagrelor (AR-C124910XX) dosing adjustment based on various intrinsic factors such as age, gender, ethnicity, renal impairment, end-stage renal disease on hemodialysis, and hepatic impairment. The table indicates that there is no dose adjustment required for these intrinsic factors except for the note that BRILINTA has not been studied in patients with moderate or severe hepatic impairment.*
FDA Label Image

Figure_9 (Image 09)

Figure_9 (Image 09)
This text provides information on the interaction of Ticagrelor (a drug used to prevent blood clots) with other medications. It includes details on recommended dosages and adjustments for drugs such as Simvastatin, Amlodipine, Levonorgestrel, Ethinyl Estradiol, Torasemide, Digoxin, and Cyclosporine. The text also references the mean effect and 90% confidence intervals for these interactions.*
FDA Label Image

60 mg 60 Count Label (Image 60)

60 mg 60 Count Label (Image 60)
Each tablet contains 60 mg of ticagrelor. This medication needs to be stored at a temperature between 20° to 25°C (68° to 77°F) and kept out of reach of children. It is important to read the package insert for the usual adult dosage information. Distributed by Oryza Pharmaceuticals, Inc. and manufactured by Sunshine Lake Pharma Co., Ltd. This product contains 60 tablets of ticagrelor.*
FDA Label Image

Logo (Logo0001 01)

Logo (Logo0001 01)
FDA Label Image

Logo0001-02 (Logo0001 02)

Logo0001-02 (Logo0001 02)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.